Cardinal Health sales rallies to $67.5B as adjusted earnings rise

Cardinal Health (NYSE:CAH) reported first-quarter fiscal 2027 revenue of $67.5 billion, up 5% year over year, while non-GAAP diluted earnings per share increased 28% to $3.26.

GAAP operating earnings increased 13% to $753 million, while non-GAAP operating earnings rose 17% to $1 billion, compared with $857 million in the prior-year quarter.

Net earnings attributable to Cardinal Health increased 23% to $554 million, while GAAP diluted EPS rose 27% to $2.38.

The company also completed a $500 million accelerated share repurchase programme during the quarter.

Cardinal Health raised its FY2027 non-GAAP EPS guidance to $12.80–$13.00 from $12.40–$12.60, representing expected growth of 17%–19% against its adjusted FY2026 baseline, while also increasing its pharmaceutical segment profit growth forecast to 10%–12%.

Following the November 5 announcement, Cardinal Health shares traded at approximately $264.34 in premarket activity, up about 0.9% from the previous regular-session close of $261.93.

Cardinal Health distributes pharmaceutical and specialty products, manufactures and supplies medical and laboratory products, and provides healthcare logistics, home-health services and data solutions to hospitals, pharmacies and healthcare providers.

The company is extending its pharmaceutical distribution relationship with CVS Health through June 2032, developing its INSIGHT-IBD real-world evidence study with Eli Lilly and expanding its financing capacity through an additional $1 billion in uncommitted revolving credit facilities.